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RESUMO 
Introdução: A fração de ejeção do ventrículo esquerdo é um dos parâmetros mais 
usados na estratificação do risco dos doentes após enfarte agudo do miocárdio. Apesar 
daqueles que evoluem com uma fração de ejeção do ventrículo esquerdo preservada 
parecerem ter um melhor prognóstico, em oposição àqueles com fração de ejeção do 
ventrículo esquerdo reduzida, os primeiros têm uma taxa de eventos cardiovasculares 
significativa. Com este trabalho pretendemos descrever o prognóstico e os fatores de 
risco deste subgrupo de doentes. 
Métodos: Estudamos doentes referenciados para o programa de reabilitação cardíaca 
após enfarte agudo do miocárdio, entre Janeiro de 2010 e Dezembro de 2012. Estes 
tinham de ter fração de ejeção do ventrículo esquerdo >=50% à data da alta (medida por 
ecocardiografia transtorácica) e completado o programa de reabilitação cardíaca. Os 
dados laboratoriais foram colhidos a partir de medição de análises sanguíneas durante o 
internamento. O outcome composto foi definido como morte de qualquer causa, 
hospitalização por insuficiência cardíaca, diagnóstico de novo ou agravamento da 
insuficiência cardíaca no doente seguido em ambulatório. 
Resultados: Os 235 doentes estudados tinham uma média de idades de 60±11 anos e 
80% eram homens. Durante o seguimento de 3.2±4.1 anos, 31 (13%) sofreram o 
outcome composto (19 diagnósticos de novo de insuficiência cardíaca, 6 hospitalizações 
e 6 mortes). Os doentes que tiveram um evento eram mais velhos (68 anos vs 59 anos, P 
= 0.001), e tinham uma maior prevalência de hipertensão (81% vs 62%, P = 0.044) e 
diabetes (55% vs 28%, P = 0.003). Houve menos enfartes agudos do miocárdio sem 
supra-ST no grupo de doentes que tiveram um evento (32% vs 41%, P = 0.001). Estes 
tiveram uma classe Killip superior durante o internamento (classe II-IV: 28% vs 4.9%; 
P < 0.001) e doença coronária arterial mais grave (55% com doença de três vasos vs 
30%, P = 0.06). Houve também maior prevalência de doença renal crónica (26% vs 6%, 
P < 0.001) e anemia (45% vs 18%, P < 0.001) neste subgrupo. Não foram encontradas 
diferenças significativas nos dados ecocardiográficos entre os dois grupos. Os níveis 
plasmáticos de péptido natriurético do tipo-B N-terminal durante o internamento foram 
mais altos nos doentes que eventualmente tiveram um evento (mediana 408 [207-799] 
ng/mL vs 342 [124-569] ng/mL; P = 0.018). Depois de ajustados para o sexo e idade, 
apenas a diabetes (HR-1.93; 95% CI: 1.12-4.24) e a classe Killip (HR-2.15; 95% CI: 
1.15-4.02) mantiveram-se significativamente associados ao outcome incidente. O 
péptido natriurético do tipo-B N-terminal não manteve o seu valor prognóstico 
significativo (HR-1.24; 95%CI: 0.88-1.76).  
Conclusão: Os doentes pós-enfarte agudo do miocárdio não têm o prognóstico benigno 
sugerido pela fração de ejeção do ventrículo esquerdo preservada. São necessários mais 
estudos que avaliem a utilidade da diabetes, níveis plasmáticos de péptido natriurético 
do tipo-B N-terminal e novos parâmetros ecocardiográficos de forma a identificar 
aqueles com maior risco dentro deste grupo específico de doentes. 
Palavras-chave: fração de ejeção do ventrículo esquerdo preservada; pós-enfarte agudo 
do miocárdio; péptido natriurético. 
 
  
ABSTRACT 
Introduction: Left ventricular ejection fraction (LVEF) has long been the key 
parameter used to stratify the risk in patients after an acute myocardial infarction (AMI). 
Although patients evolving with a preserved LVEF seem to have a better prognosis 
opposed to those with a reduced LVEF, they may have a significant rate of 
cardiovascular (CV) events. We aimed to describe the prognosis and its risk factors in 
this often overlooked subgroup of patients. 
Methods: We studied patients referred to a cardiac rehabilitation (CR) program after an 
acute myocardial infarction (AMI) between January 2010 and December 2012. They 
had to have a LVEF >=50% at the time of hospital discharge (measured by transthoracic 
echocardiography) and completed CR program. The laboratorial data was collected 
from blood analysis measurement during hospitalization. The composite outcome was 
defined as all-cause death, heart failure hospitalization, de novo diagnosis or worsening 
HF at the outpatient clinic, and it was assessed by chart review. 
Results: The 235 studied patients had a mean age of 60±11 years and 80% were male. 
During a follow-up of 3.2±4.1 years, 31 (13%) had a composite outcome (19 de novo 
HF diagnosis, 6 HF hospitalizations and 6 deaths). Patients who had an event were older 
(68 years vs 59 years, P = 0.001), and had a higher prevalence of hypertension (81% vs 
62%, P = 0.044) and diabetes (55% vs 28%, P = 0.003). There were fewer STEMIs in 
the group with an event (32% vs 41%, P = 0.001). They had higher Killip class during 
hospitalization (class II-IV: 28% vs 4.9%; P < 0.001) and more severe CAD (55% with 
three-vessel disease vs 30%, P = 0.06). Higher prevalence of chronic kidney disease 
(CKD) (26% vs 6%, P < 0.001) and anemia (45% vs 18%, P < 0.001) was also present 
in this subgroup. No significant difference regarding echocardiographic data was 
present between groups. N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) 
plasma levels during hospitalization were higher in the subset of patients that eventually 
had an event (median 408 [207-799] ng/mL vs 342 [124-569] ng/mL; P = 0.018). After 
adjusting for sex and age, only diabetes (HR-1.93; 95% CI: 1.12-4.24) and Killip class 
(HR-2.15; 95% CI: 1.15-4.02) remained significantly associated with incident outcome. 
NT-pro-BNP did not keep its significant prognostic value (HR-1.24; 95%CI: 0.88-1.76).  
 
Conclusions: These post-AMI patients did not have the benign prognosis that could be 
suggested by the preserved LVEF. Further studies are needed to examine the utility of 
diabetes, NT-pro-BNP plasma levels and new echocardiographic parameters to identify 
those at higher risk among this specific group of post-AMI patients. 
Key-words: Preserved left ventricle ejection fraction; post-acute myocardial infarction; 
natriuretic peptide. 
 
  
INTRODUCTION 
Heart failure (HF) is a major cause of morbidity and mortality in developed 
countries, as well as impaired quality of life. Moreover, it is rapidly becoming a serious 
economic burden for the healthcare systems across Western societies. 
For the past decades, HF and its two subtypes, HF with reduced ejection fraction 
(HFrEF) and HF with preserved ejection fraction (HFpEF), had been the aim of many 
studies [1-3]. HFpEF represents half of HF diagnosis and its prevalence is increasing, 
particularly among the elderly and women [4-6]. Despite all efforts, there’s no treatment 
available capable of modifying the prognosis of these patients [7-10]. Their 
heterogeneity has led the scientific community to approach HFpEF’s different 
phenotypes, that are generally based on their comorbidities, such as arterial 
hypertension, diabetes, obesity, coronary heart disease (CAD), chronic kidney disease 
(CKD), among others. [11, 12]. 
CAD seems to play a key role, with a prevalence that ranges from 35% to 53% 
in HFpEF patients [5, 13] In fact, acute coronary syndromes often lead to HF 
decompensation and subsequently to hospitalisation [14]. As expected, patients with 
CAD and HFpEF suffer a greater left ventricular (LV) dysfunction and have a worse 
prognosis, when compared to HFpEF patients without CAD [15, 16]. In parallel, the 
clinical landscape of post-AMI patients had been changing during the last decades due 
to the efficacy and the greater availability of emergent percutaneous coronary 
revascularization. Along with improvements in pharmacological therapy, this led to an 
increased prevalence of acute myocardial infarctions (AMI) evolving with a preserved 
left ventricular ejection fraction (LVEF) [17]. Despite the major advances in the 
treatment of this condition, studies have shown that patients with a preserved LVEF 
post-AMI still have a significant number of cardiovascular events, such as progression 
to HF in up to one third [18] and sudden cardiac death (SCD), the main cause of death 
in post-AMI with preserved LVEF [19]. 
Similarly to HF, LVEF is an important prognostic factor in CAD patients. This 
key parameter is commonly used to assess prognosis. However, LVEF alone is a very 
limited tool, because post-AMI patients with a LVEF above 50% can be a rather 
heterogeneous group, holding significant different prognosis. For this reason, it is 
important to look for other tools to better prognosticate these patients. Little data is 
available on the utility of other clinical, echocardiographic and plasma biomarkers to 
stratify either the mortality and HF incidence in this subgroup of patients. 
The present study aimed to investigate the prognostic value of clinical features, 
cardiac phenotype and serum levels of N-terminal pro-brain natriuretic peptide (NT-pro-
BNP) in post-AMI patients with preserved LVEF. 
 
METHODS 
We studied 235 consecutive patients referred to a cardiac rehabilitation (CR) 
program after an acute myocardial infarction (AMI) between January 2010 and 
December 2012 at Hospital Santo António, Centro Hospitalar do Porto, who presented a 
LVEF >=50% at the time of discharge and completed that same program. Clinical, 
laboratorial, and echocardiographic data were collected by chart review. This study 
conforms with the principles outlined in the Declaration of Helsinki and was approved 
by the institution's ethical committee (N/REF.ª 2016.236(199-DEFI/188-CES). 
 Supine transthoracic echocardiography was performed in all patients before the 
hospital discharge. LVEF was either calculated using the biplane Simpson method or 
eye-balling. We excluded patients with a reported LVEF lower than 50%. Dimensions 
and volumes of cardiac chambers and left ventricular mass were measured according to 
current international recommendations [20]. The laboratorial data was collected from 
blood analysis measurement during hospitalization. NT-pro-BNP was measured using 
the Roche® NT-pro-BNP assay. Anemia was defined as hemoglobin less than 12 g/dL 
for women and less than 13 g/dL for men. CKD was defined as estimated glomerular 
filtration rate (eGFR) < 60 ml/min/ 1.73 m2. 
Incident outcome events were defined as the first occurrence of all-cause death, 
heart failure hospitalization, or de novo diagnosis (if explicitly stated at clinical notes of 
assistant physician or diuretics were uptitrated). All events were collected by chart 
review. 
  
Statistical analysis 
Continuous variables are expressed as mean ± standard deviation for normally 
distributed data or median [25th, 75th percentiles] for non-normally distributed data. 
Categorical variables are expressed as number of subjects and proportion [n (%)]. 
Comparisons between groups were performed using 2-sided unpaired or paired t tests or 
Wilcoxon rank sums test for normally and non-normally distributed data, respectively. 
Fisher’s exact test was applied to compare proportions. One-way ANOVA with 
Bonferroni correction was used to perform multiple group comparisons. Correlations 
between hemodynamic and metabolic variables were determined using Pearson or 
Spearman correlation for normally and non-normally distributed data, respectively. We 
used univariate and multivariable Cox proportional hazards regression models to assess 
the unadjusted and adjusted association of clinical and echocardiography features and 
pro-BNP with the composite outcome. The proportional hazards assumption was 
assessed by visual inspection of Schoenfeld residuals. Statistical analysis was performed 
using Stata software Version 12.1 (Stata Corp LP, College Station, TX, USA). A two-
sided p-value <0.05 was considered significant. 
 
RESULTS 
Studied population 
The 235 patients included in this analysis had a mean age of 60±11 years and 
were predominantly male (80%). Their baseline clinical characteristics are shown in 
Table 1. Patients with an event were older and had a higher prevalence of several 
cardiovascular risk factors such as hypertension and diabetes. They were also more 
inclined to have known CAD, history of atrial fibrillation, and stroke, but presented 
similar prevalence of other comorbidities such as dyslipidemia, COPD and OSA. 
 Regarding the ACS event, the group that didn’t suffer an event tended to have a 
higher proportion of ST-segment elevation myocardial infarction (STEMI) (41%). On 
the other hand, significant differences were found regarding the Killip class, with 
patients who had an event post-AMI presenting with a higher class (24% in class II and 
4% at class III). We also found an increased severity of CAD, with 55% of patients who 
had an event suffering of a three-vessel disease. We did not observe any difference 
regarding the culprit coronary lesion. Patients that eventually had an event were more 
likely to have atrial fibrillation during hospitalization. 
 Regarding laboratory data, patients who eventually had an event had a worse 
renal function, with a significant GFR value lower than those who didn’t have an event, 
as well as a higher proportion of patients with CKD. Hemoglobin levels at discharge 
were also lower in this subgroup, with 45% of patients presenting anemia, as well as 
higher values of NT-pro-BNP (available in 72% of the overall patients, ordered by 
physician assistant discretion). In contrast, no differences in peak CK and TnT were 
found in our analysis. 
 No significant discrepancies were observed at discharge medications, but 
diuretics were more often prescribed to patients that eventually had an event. 
Echocardiographic data 
 Patients that developed a clinical event trended to have an increased LV mass 
and larger left atria. No other differences were found between these groups relating 
structural and functional variables in transthoracic echocardiography – Table 2. 
Outcomes 
Of the 235 patients, 31 (13%) had a composite outcome (19 de novo HF 
diagnosis, 6 HF hospitalizations and 6 deaths) over a 3.2±4.1 years of follow-up. The 
overall incidence was 3.4 (95% CI: 2.3-4.9) 100 person-years. The unadjusted analysis 
is displayed in Table 3. After adjusting for sex and age, only diabetes (HR-1.93; 95%CI: 
1.12-4.24) and Killip class (HR-2.15; 95%CI: 1.15-4.02) remained significantly 
associated with incident outcome. NT-pro-BNP did not keep its significant prognostic 
value (HR-1.24; 95%CI: 0.88-1.76). 
 
  
DISCUSSION 
Our analysis yield four key findings. Firstly, post-AMI patients with preserved 
LVEF have a significant rate of CV events. Secondly, our studied population was older 
and had a high prevalence of comorbidities, namely diabetes, an important prognosis 
factor for this subgroup of patients. Thirdly, NT-pro-BNP was independently associated 
with composite outcomes, but, after adjusting for demographic features in a multivariate 
analysis, only Killip class during hospitalizations prevailed as an independent 
prognostic marker. Finally, conventional echocardiographic measurements couldn’t 
predict outcome in this subgroup of patients with preserved LVEF. 
In this study, post-AMI patients with preserved LVEF had a significant CV 
event rate of 5% per year. Since post-AMI patients with preserved LVEF have a better 
prognosis than the ones with reduced LVEF [21], this rate may be higher than expected. 
This reminds us that although they presented with preserved LVEF at the time of 
discharge, some of them had clinical features that significantly influenced their 
prognosis. Some studies that compared outcomes in HFpEF and HFrEF concluded that 
patients with preserved EF had a lower death rate (13% vs 21%) and were significantly 
associated with a better survival after adjusting for demographic features. The 
proportion of deaths attributed to cardiovascular events is also lower in HFpEF (ranging 
from 50%-70% vs 60%-80%) [22]. Others state that, regarding all-cause readmission or 
HF hospitalization, there wasn’t an association between preserved EF and this increased 
risk (HR 1.01 and HR 0.77, respectively) [23]. Despite that, the comparison with 
previous studies is problematic, because we used a composite outcome that included all-
cause death and HF-related events. However, we may be underestimating the prognosis 
severity as we only included post-AMI patients who were enrolled and completed CR 
program, who usually are the healthiest ones among post-AMI cohorts. 
 Diabetes is a common comorbidity in CAD patients and it was more prevalent in 
patients who eventually developed the composite event, remaining significantly 
associated with the incident outcome, after adjusting for demographic features. It is well 
known that patients with diabetes have a poorer short-term and long-term prognosis 
after an AMI, when compared to non-diabetic patients [24, 25]. In fact, despite the 
management of diabetic and non-diabetic patients after an acute coronary syndrome 
(ACS) being comparable, studies have not demonstrated a similar reduction in 
cardiovascular mortality, even though they’re subjected to the most modern therapy 
available [26, 27]. This might be explained by the fact that diabetes constitutes a major 
risk factor for atherosclerosis, which in turn leads to coronary artery disease. Moreover, 
hyperglycemia and insulin-resistance have also been associated with the dysregulation 
of several signalling pathways responsible for platelets reactivity, leading to an increase 
of thrombotic events, such as AMI [28]. This dysregulation also contributes to a lower 
success rate of antithrombotic therapies and a lesser extent of STEMI resolution [29]. 
Besides the prognostic implications in post-ACS patients, diabetes also plays a role in 
the development of HF, particularly HFpEF, which appears to be more common among 
diabetic patients [30-32]. Pathophysiological mechanisms such as cardiac hypertrophy 
and fibrosis, metabolic dysfunction of the muscle, which lead to relaxation and 
microvascular abnormalities, might explain the increased prevalence of HFpEF in this 
subgroup. Other studies name the processes that impact negatively the cardiac muscle of 
diabetic patients with no other comorbidities “diabetic cardiomyopathy” [33], which 
highlights the need for a tighter control of the glycemia. Even patients without known 
CAD are at higher risk of developing a fatal or nonfatal CV event when diabetes and 
microalbuminuria, as well as elevated NT-pro-BNP, are present [34].  
In this study, another key parameter analyzed was NT-pro-BNP, an important 
biomarker whose plasma levels tend to be elevated in patients with left ventricular 
impairment. Increased wall stress and LV volume overload, with consequent 
cardiomyocyte stretching and neurohormonal activation, upregulates the release of the 
peptide in response to these stimuli [35, 36]. It is also the cornerstone parameter for the 
diagnosis and management of HF, as well as a potent predictor of short and long-term 
mortality in this subset of patients [37-41]. In our study, higher values of NT-pro-BNP 
were associated with a higher rate of events in the studied population (Figure 1). 
However, this significant association with composite outcome did not persist after 
adjusting for age and sex, remaining only significantly associated diabetes and Killip 
class. Previous studies have shown that NT-pro-BNP is able to independently predict 
incident heart failure and death, regardless of LVEF and, for those with systolic 
dysfunction, it signals the risk of developing new ischemic events [42]. Others 
concluded that NT-pro-BNP was a valuable marker to predict the severity of CAD, 
namely the number of vessels involved and the degree of stenosis [43, 44] Accordingly, 
our data shows that the majority of patients in the events subset had a significant rate of 
three-vessels disease (54.8%). In spite of not showing statistical significance after 
adjusting for demographic features, our results show some correlation between NT-pro-
BNP and incident outcome (Figure 2). This suggests that the natriuretic peptide might 
have a potential benefit in reducing the underdiagnosis of HF during hospital stay, as 
well as stratifying risk in these populations, which would help assess those in need of a 
more aggressive treatment approach. Multiple studies have already proven the 
usefulness of this biomarker. The risk assessment and MACE prediction in patients 
undergoing diagnostic coronary angiography with a score that included NT-pro-BNP 
[45] and it’s use complemented with high-sensitivity C-reactive protein (hs-CRP) to 
predict mortality risk and MI risk in patients with non–ST-segment elevation ACS [46] 
are some examples of this. 
Another relevant finding of this study was that none of the conventional 
echocardiographic measurements predicted the outcome in this subgroup of patients. As 
traditional echocardiographic parameters depend on single measurements, they are 
representative only in normally shaped ventricles and may be blind to more subtle shape 
distortions, not visible in the 2 or 4 chambers planes. Moreover, since adverse 
remodelling develops in a complex process over weeks to months after AMI, the initial 
abnormalities may be so tenuous that they do not reflect structure changes at this time. 
Lately, new imaging tools have emerged as a more sensitive index of LV function and 
mechanics after AMI. Myocardial strain measures the relative change in length of 
myocardium through the cardiac cycle. As global longitudinal strain is less susceptible 
to factors that limit EF [21], it may be a better indicator for LV contractile function and 
mechanics than LVEF [22]. Global longitudinal strain measured acutely by Speckle 
Tracking Echocardiography post-STEMI had been shown to be independently 
associated with LV dilatation at follow-up [23] and strongly correlated with adverse 
events [24].  However, despite being proved to be predictive for LV remodelling, this 
tool is not currently widely available and limited data is available regarding the 
prognostic utility in HFpEF patients [25-27]. Further research is needed to better stratify 
these patients’ risks. 
Our study has several limitations that need to be considered. We cannot avoid 
the inherent biases to the retrospective design. By selecting patients who underwent 
cardiac rehabilitation program, we can’t extrapolate our findings to all ACS patients. 
The single center data limits inference to a broader population. The small sample size 
and reduced event rate limits our statistical power to examine the prognostic effect of 
some of the studied variables. Therefore, we cannot exclude the possibility of a type 2 
error in those negative associations we found, such as NT-pro-BNP. We analysed a 
composite outcome that may hamper more straightforward interpretation of our survival 
data. 
 
CONCLUSION 
These post-AMI patients did not have the benign prognosis that could be 
suggested by the preserved LVEF. Further studies are needed to examine the utility of 
diabetes, NT-pro-BNP plasma levels and new echocardiographic parameters to identify 
those at higher risk among this specific group of post-AMI patients.  
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TABLES 
Table 1 – Clinical characteristics of studied patients. 
Characteristic Overall 
(N=235) 
Without 
event 
(n=204) 
With event 
(n=31) 
P-value 
Age, y 59.81 ± 10.80 58.64 ± 10.52 67.55 ± 9.48 < 0.001 
Male, n (%) 187 (79.6%) 168 (82.4%) 19 (61.3%) 0.007 
BMI, Kg/m2 26.56 ± 4.01 26.51 ± 4.13 26.89 ± 3.16 0.63 
Hypertension, n (%) 151 (64.5%) 126 (62.1%) 25 (80.6%) 0.044 
Smoking status 
   Never smoked, n (%) 
   Past smoker, n (%) 
   Current smoker, n 
(%) 
 
86 (36.6%) 
87 (37.0%) 
62 (26.4%) 
 
68 (33.3%) 
82 (40.2%) 
54 (26.5%) 
 
18 (58.1%) 
5 (16.1%) 
8 (25.8%) 
0.013 
Diabetes, n (%) 74 (31.6%) 57 (28.1%) 17 (54.8%) 0.003 
Dyslipidemia, n (%) 174 (74.4%) 150 (73.9%) 24 (77.4%) 0.68 
History of atrial 
fibrillation, n (%) 
5 (2.1%) 3 (1.5%) 2 (6.5%) 0.07 
Stroke, n (%) 7 (3.0%) 5 (2.5%) 2 (6.5%) 0.22 
CAD, n (%) 44 (18.7%) 35 (17.2%) 9 (29.0%) 0.11 
COPD, n (%) 9 (3.8%) 8 (3.9%) 1 (3.2%) 0.85 
OSA, n (%) 4 (1.7%) 4 (2.0%) 0 (0.0%) 0.43 
ACS hospitalization 
features 
    
STEMI, n (%) 92 (39.5%) 82 (40.6%) 10 (32.3%) 0.38 
Killip class 
    II, n (%) 
    III, n (%) 
    IV, n (%) 
 
11 (5.9%) 
3 (1.6%) 
1 (0.5%) 
 
5 (3.1%) 
2 (1.2%) 
1 (0.6%) 
 
6 (24.0%) 
1 (4.0%) 
0 (0.0%) 
< 0.001 
Number of coronaries 
with significant disease 
   One-vessel, n (%) 
 
 
 
 
 
 
 
 
 
0.06 
   Two-vessel, n (%) 
   Three-vessel, n (%) 
85 (37.0%) 
67 (29.1%) 
77 (33.5%) 
78 (39.2%) 
60 (30.2%) 
60 (30.2%) 
7 (22.6%) 
7 (22.6%) 
17 (54.8%) 
Culprit coronary    0.95 
   LAD, n (%) 90 (39.8%) 79 (40.3%) 11 (36.7%)  
   RCA, n (%) 90 (39.8%) 77 (39.3%) 13 (43.3%)  
   LCx, n (%) 45 (19.9%) 39 (19.9%) 6 (20.0%)  
PCI, n (%) 204 (87.6%) 176 (86.7%) 28 (93.3%) 0.77 
Atrial fibrillation, n 
(%)  
10 (4.3%) 7 (3.4%) 3 (10.0%) 0.10 
Blood analysis at 
discharge 
    
GFR, mL/min/1.73 m2 85.82 ± 17.44 87.55 ± 16.47 75.02 ± 19.65 < 0.001 
GFR < 60 
mL/min/1.73 m2, n 
(%) 
20 (8.5%) 12 (5.9%) 8 (25.8%) < 0.001 
Hb, g/dL 13.56 ± 1.37 13.68 ± 1.24 12.75 ± 1.82 < 0.001 
Anemia, n (%) 50 (21%) 36 (18%) 14 (45%) <0.001 
Peak CK, U/L 636.16 ± 
910.38 
647.97 ± 
862.62 
561.38 ± 
1184.31 
0.63 
Peak TnT, ng/mL 1.19 ± 1.54 1.22 ± 1.56 1.01 ± 1.47 0.57 
NT-pro-BNP, ng/mL 347 [129-
632] 
342 [124-
569] 
408 [207-
799] 
0.018 
Medication at 
discharge 
    
Aspirin, n (%) 231 (98.7%) 200 (98.5%) 31 (100.0%) 0.50 
Clopidogrel/Ticagrelor, 
n (%) 
 227 (97.0%) 196 (96.6%) 31 (100.0%) 0.29 
Statin, n (%) 223 (95.3%) 193 (95.1%) 30 (96.8%) 0.68 
B-Blocker, n (%) 209 (89.3%) 182 (89.7%) 27 (87.1%) 0.67 
ACEI/ARB, n (%) 159 (68.5%) 137 (68.2%) 22 (71.0%) 0.75 
Diuretic, n (%) 14 (6.0%) 6 (2.9%) 8 (25.8%) < 0.001 
MRA, n (%) 2 (0.9%) 2 (1.0%) 0 (0.0%) 0.58 
Caption: BMI, Body Mass Index; HF, Heart Failure; CAD, Coronary Artery Disease; 
COPD, Chronic Obstructive Pulmonary Disease; OSA, Obstructive Sleep Apnea; ACS, 
Acute Coronary Syndrome; STEMI, ST Segment Elevation Myocardial Infarction; 
LAD, Left Anterior Descending Artery; RCA, Right Coronary Artery; LCx, Left 
Circumflex Artery; PCI, Percutaneous Coronary Intervention; GFR, Glomerular 
Filtration Rate; Hb, Hemoglobin; CK, Creatine Kinase; TnT, Troponine T; NT-pro-
BNP, N-terminal pro-B-type natriuretic peptide; ACEI/ARB, Angiotensin-converting-
enzyme Inhibitor/Angiotensin II Receptor Blocker; MRA, Mineralocorticoid Receptor 
Antagonist. 
  
Table 2 – Echocardiographic features of studied patients. 
Characteristic Overall 
(N=235) 
No event 
(n=204) 
Event (n=31) P-value 
IVS, mm 11.77 ± 1.99 11.81 ± 2.04 11.57 ± 1.65 0.54 
PWT, mm 10.50 ± 1.33 10.50 ± 1.31 10.53 ± 1.50 0.89 
LV mass 
indexed, g/m2  
102±22 102±22 106±25 0.29 
LVEDD, mm 46.02 ± 4.80 45.93 ± 4.88 46.60 ± 4.31 0.48 
LVESD, mm 29.63 ± 4.94 29.64 ± 5.11 29.57 ± 3.60 0.95 
LA diameter, 
mm 
38.74 ± 4.63 38.49 ± 4.61 40.40 ± 4.54 0.035 
LA area, cm2 20.21 ± 4.17 19.98 ± 3.99 21.81 ± 5.03 0.032 
Segmental 
motion 
abnormalities 
    
Anterior, n (%)   
52 (22.2%) 
46 (22.5%) 6 (20.0%) 0.75 
Posterior, n (%) 87 (37.0%) 75 (36.8%) 12 (38.7%) 0.83 
Inferior, n (%) 131 (55.7%) 112 (54.9%) 19 (61.3%) 0.50 
Moderate/severe 
MR, n (%) 
3 (1.3%) 3 (1.5%) 0 (0.0%) 0.49 
RV systolic 
dysfunction, n 
(%) 
4 (1.7) 3 (1.5%) 1 (3.2%) 0.50 
LV 
remodelling 
pattern 
    
   Normal, n (%) 51 (21.7%) 44 (21.6%) 7 (22.6%) 0.40 
   Concentric, n 
(%) 
98 (41.7%) 87 (42.6%) 11 (35.5%)  
   Concentric 
LVH, n (%) 
66 (28.1%) 54 (26.5%) 12 (38.7%)  
   Eccentric 
LVH, n (%) 
20 (8.5%) 19 (9.3%) 1 (3.2%)  
Caption: IVS, Interventricular Septum; PWT, Posterior Wall Thickness; LVEDD, Left 
Ventricular End Diastolic Diameter; LVESD, Left Ventricular End Sistolic Diameter; 
LA, Left Auricle; MR, Mitral Regurgitation; LV, Left Ventricle; LVH, Left Ventricular 
Hypertrophy. 
  
Table 3 – Unadjusted hazard ratios for incident composite outcome.  
 Univariate Hazard 
Ratio (95% CI) 
P-value 
Age 1.09 (1.05-1.13) <0.001 
Male sex 0.40 (0.18-0.85) 0.017 
Hypertension 2.09 (0.84-5.17) 0.112 
Diabetes 2.43 (1.14-5.17) 0.021 
STEMI 0.92 (0.41-2.05) 0.838 
Killip class 2.20 (1.24-3.91) 0.007 
Hemoglobin 0.68 (0.54-0.85) 0.001 
GFR 0.97 (0.95-0.99) 0.001 
NT-pro-BNP* 1.45 (1.01-2.07) 0.04 
LV mass 1.01 (0.99-1.03) 0.212 
LA area 1.09 (1.01-1.17) 0.024 
Caption: *log-NT-pro-BNP. 
 
 
 
  
FIGURES 
Figure 1 - Events rate across NT-pro-BNP quartiles. Q1 = 68 [41-102] ng/mL; Q2 = 
228 [177-292] ng/mL; Q3 = 426 [388-528] ng/mL; Q4 – 1042 [809-1620] ng/mL. 
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Figure 2 - Incidence spline of NT-pro-BNP and composite event rate. Incidence 
rate’s unit is 100 person-year and NT-pro-BNP was converted to logNT-pro-BNP. 
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